IGX Archives - BioTuesdays

Developments

IntelGenx receives first RIZAFILM purchase order from U.S. partner Gensco

IntelGenx (TSX:IGX; OTCQB:IGXT) reported that it received the first purchase order (PO) for RIZAFILM from its U.S. commercial partner, Gensco Pharma. The company expects to ship the order to Gensco in the first quarter...

September 21, 2023

Developments

IntelGenx receives FDA GDUFA date for partnered buprenorphine buccal film

IntelGenx’s (TSX:IGX; OTCQB:IGXT) buprenorphine buccal film – for which an amendment to the abbreviated to new drug application (ANDA) requesting priority review has been filed by Chemo Research through its agent and...

September 20, 2023

Developments

IntelGenx first CDMO packaging accord to generate $9-million in revenue over 3 years

IntelGenx (TSX:IGX; OTCQB:IGXT) expects to generate $9-million in revenue over three years from an agreement for packaging a pharmaceutical oral film product that an undisclosed contract development and manufacturing...

August 11, 2023

Developments

IntelGenx completes enrollment in Montelukast VersaFilm Phase 2a trial in AD

IntelGenx (TSX:IGX; OTCQB:IGXT) completed patient enrollment in the ongoing Montelukast VersaFilm Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD). The company successfully...

August 1, 2023

Developments

IntelGenx updates Montelukast VersaFilm collaboration for Parkinson’s

IntelGenx (TSX:IGX; OTCQB:IGXT) finalized a research grant agreement with Sweden’s Karolinska University Hospital and that the manufacturing of both active and placebo films are underway for a planned multicentre...

July 25, 2023

Developments

IntelGenx unveils short-term commercial objectives

IntelGenx (TSX:IGX; OTCQB:IGXT) unveiled a plan focussed on near-term revenue generation. “There is no question in my mind that IntelGenx has great science, services, assets, and people,”Dwight Gorham, the company’s...

May 31, 2023

Developments

IntelGenx receives amended Health Canada license for third-party testing

IntelGenx (TSX:IGX; OTCQB:IGXT) received an amended Drug Establishment License (DEL) from Health Canada, allowing the company to conduct third-party testing. Analytical testing of finished products and intermediates is...

May 17, 2023

Developments

FDA approves IntelGenx’s RIZAFILM for acute migraine

The FDA has approved IntelGenx’s (TSX:IGX; OTCQB:IGXT) RIZAFILM VersaFilm 505(b)(2) new drug application for the treatment of acute migraine. RIZAFILM is a proprietary oral thin film formulation of rizatriptan benzoate...

April 17, 2023

Executive Moves

IntelGenx makes organizational changes to support global growth strategy

IntelGenx Technologies (TSX:IGX; OTCQB:IGXT) appointed Dwight Gorham as CEO, effective immediately, succeeding the company’s founder, Horst Zerbe, Ph.D., who has retired as CEO, but will continue as chairman. The CEO...

April 13, 2023

Developments

IntelGenx receives USPTO notice of allowance for loxapine Orange Book eligible patent

The United States Patent and Trademark Office has granted a notice of allowance for IntelGenx’s (TSX:IGX; OTCQB:IGXT) U.S. patent application entitled, “Loxapine Film Oral Dosage Form.” The film formulation patent...

February 21, 2023

Tag - IGX

IntelGenx receives first RIZAFILM purchase order from U.S. partner Gensco

IntelGenx receives FDA GDUFA date for partnered buprenorphine buccal film

IntelGenx first CDMO packaging accord to generate $9-million in revenue over 3 years

IntelGenx completes enrollment in Montelukast VersaFilm Phase 2a trial in AD

IntelGenx updates Montelukast VersaFilm collaboration for Parkinson’s

IntelGenx unveils short-term commercial objectives

IntelGenx receives amended Health Canada license for third-party testing

FDA approves IntelGenx’s RIZAFILM for acute migraine

IntelGenx makes organizational changes to support global growth strategy

IntelGenx receives USPTO notice of allowance for loxapine Orange Book eligible patent

General

More